These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21099346)

  • 1. Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib.
    Lee SA; Lee MS; Ryu HW; Kwak TK; Kim H; Kang M; Jung O; Kim HJ; Park KH; Lee JW
    Cancer Biol Ther; 2011 Feb; 11(3):330-6. PubMed ID: 21099346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative.
    Lee SA; Ryu HW; Kim YM; Choi S; Lee MJ; Kwak TK; Kim HJ; Cho M; Park KH; Lee JW
    Hepatology; 2009 Apr; 49(4):1316-25. PubMed ID: 19177595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
    Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmembrane 4 L six family member 5 (TM4SF5) enhances migration and invasion of hepatocytes for effective metastasis.
    Lee SA; Kim TY; Kwak TK; Kim H; Kim S; Lee HJ; Kim SH; Park KH; Kim HJ; Cho M; Lee JW
    J Cell Biochem; 2010 Sep; 111(1):59-66. PubMed ID: 20506553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
    Nagai T; Arao T; Furuta K; Sakai K; Kudo K; Kaneda H; Tamura D; Aomatsu K; Kimura H; Fujita Y; Matsumoto K; Saijo N; Kudo M; Nishio K
    Mol Cancer Ther; 2011 Jan; 10(1):169-77. PubMed ID: 21220499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.
    Bai S; Nasser MW; Wang B; Hsu SH; Datta J; Kutay H; Yadav A; Nuovo G; Kumar P; Ghoshal K
    J Biol Chem; 2009 Nov; 284(46):32015-27. PubMed ID: 19726678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of signaling between TM4SF5 and integrins in tumor microenvironment.
    Lee SA; Park KH; Lee JW
    Front Biosci (Landmark Ed); 2011 Jan; 16(5):1752-8. PubMed ID: 21196261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
    Beljanski V; Lewis CS; Smith CD
    Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
    Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma.
    Lee SA; Lee SY; Cho IH; Oh MA; Kang ES; Kim YB; Seo WD; Choi S; Nam JO; Tamamori-Adachi M; Kitajima S; Ye SK; Kim S; Hwang YJ; Kim IS; Park KH; Lee JW
    J Clin Invest; 2008 Apr; 118(4):1354-66. PubMed ID: 18357344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
    Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonistic regulation of transmembrane 4 L6 family member 5 attenuates fibrotic phenotypes in CCl(4) -treated mice.
    Kang M; Jeong SJ; Park SY; Lee HJ; Kim HJ; Park KH; Ye SK; Kim SH; Lee JW
    FEBS J; 2012 Feb; 279(4):625-35. PubMed ID: 22177033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TM4SF5-mediated liver malignancy involves NK cell exhaustion-like phenotypes.
    Sun H; Kim E; Ryu J; Lee H; Shin EA; Lee M; Lee H; Lee JH; Yoon JH; Song DG; Kim S; Lee JW
    Cell Mol Life Sci; 2021 Dec; 79(1):49. PubMed ID: 34921636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial)].
    Detry O; Delwaide J; De Roover A; Meunier P; Van Daele D; Lamproye A; Honoré P; Polus M
    Rev Med Liege; 2009 Mar; 64(3):168-70. PubMed ID: 19418937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib.
    Ruan ZP; Xu R; Lv Y; Tian T; Wang WJ; Guo H; Nan KJ
    Oncol Res; 2012; 20(2-3):113-21. PubMed ID: 23193917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.